Across TCGA pan-cancer cohorts, MAS1L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAS1L data layer compared with 19 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher MAS1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAS1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SCLC, HNSC, and LUAD are the cancer types where MAS1L Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.